PDS Biotechnology

1 August 2019 THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF EU REGULATION 596/2014 NetScientific plc (“NetScientific” or the “Company”) PDS Biotechnology Corporation Reports Second Quarter 2019 Financial Results   NetScientific plc (AIM:NSCI), the transatlantic healthcare IP commercialisation group, announces that its portfolio company PDS Biotechnology Corporation (“PDS”) (Nasdaq: PDSB) has released its unaudited financial results for the second …

31 July 2019 THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF EU REGULATION 596/2014 NetScientific plc (“NetScientific” or the “Company”) PDS Biotechnology Corporation liquidity funding program NetScientific plc (AIM:NSCI), the transatlantic healthcare IP commercialisation group, announces that its portfolio company PDS Biotechnology Corporation (“PDS”) (Nasdaq:PDSB) has announced a liquidity funding program with Aspire Capital Fund, LLC (“Aspire”), an Illinois …

16 May 2019 NetScientific plc (“NetScientific” or the “Company”) PDS Biotechnology journal publication   NetScientific plc (“NetScientific”, AIM:NSCI), the transatlantic healthcare IP commercialisation group, announces that its portfolio company PDS Biotechnology Corporation (“PDS”) (Nasdaq:PDSB) has announced a peer-reviewed publication supporting the novel mechanisms of action of PDS’s proprietary Versamune® platform in cancer immunotherapy.   The article “Antigen Priming with Enantiospecific Cationic Lipid Nanoparticles …

19 March 2019 NetScientific plc (“NetScientific” or the “Company”) PDS merger with Edge Therapeutics update Further to its announcements on 26 November 2018 and 18 March 2019, the Company announces that its ownership of the enlarged PDS Biotechnology Corporation (“PDS”), trading on Nasdaq under the ticker PDSB, on a fully-diluted basis is 8.15%, which at the listing price on 18 March 2019 of …

Merger would create publicly-traded immuno-oncology biotechnology company developing novel products for treating early- and late-stage cancer Growing product pipeline utilising Versamune®, a novel, versatile, multi-functional platform Phase 1/2 clinical data on lead product candidate PDS0101 suggests immunotherapeutic anti-cancer activity and favourable safety profile in early stage cervical cancer Combined company plans to initiate multiple Phase 2b/3 clinical trials of PDS0101 in HPV-associated cancers …

London, UK – July 10th 2017 – NetScientific plc (“NetScientific”, AIM:NSCI), the transatlantic IP commercialisation group focused on healthcare, announces a new clinical trial collaboration agreement between its portfolio company PDS Biotechnology Corporation (“PDS”) and a subsidiary of Merck & Co., Inc. (known as MSD outside the United States and Canada). The agreement will enable PDS to evaluate the combination of its Versamune®-based PDS0101 …